Oric director granted options for 40,000 shares

Oric Pharmaceuticals director Steven L. Hoerter reported a new stock option grant for 40,000 shares of common stock.

Rhea-AI Filing Summary

Oric Pharmaceuticals director Steven L. Hoerter reported a new stock option grant for 40,000 shares of common stock. The option, with an exercise price of $8.17 per share, was awarded on January 2, 2026 and is held directly. It is scheduled to vest in equal monthly installments, with 1/12 of the shares vesting on each one-month anniversary of January 2, 2026, until fully vested. The option expires on January 1, 2036, giving the director a long-dated right to purchase Oric common shares at the fixed exercise price.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Hoerter Steven L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,000 contracts (Direct)

Footnotes (1)

1. F1. 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ORIC report in this Form 4?

The filing reports that director Steven L. Hoerter received a stock option grant for 40,000 shares of Oric Pharmaceuticals common stock on January 2, 2026.

What are the key terms of Steven L. Hoerter’s ORIC stock option?

The option covers 40,000 shares of common stock at an exercise price of $8.17 per share, was granted on January 2, 2026, and expires on January 1, 2036.

How does the 40,000-share ORIC stock option vest?

According to the footnote, 1/12th of the shares subject to the option vests on each one-month anniversary of January 2, 2026, until all 40,000 shares are vested.

Is the ORIC stock option held directly or indirectly by the reporting person?

The filing indicates the 40,000-share stock option is held directly (D) by Steven L. Hoerter, with no indirect ownership entity listed.

What role does Steven L. Hoerter have at Oric Pharmaceuticals (ORIC)?

The reporting person is identified as a director of Oric Pharmaceuticals, Inc., and is not listed as an officer or 10% owner in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 04:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoerter Steven L.

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.17	01/02/2026		A		40,000		(1)	01/01/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

	/s/ Christian Kuhlen, attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.